Previous 10 | Next 10 |
2023-08-11 04:07:07 ET Kezar Life Sciences press release ( NASDAQ: KZR ): Q2 GAAP EPS of -$0.34 in-line. Cash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2023, compared to $276.6 million as of December 31, 2022. For further detai...
PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment KZR-261 dose escalation study continues to progress and display a favorable safety and tolera...
2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...
2023-06-08 12:49:18 ET Gainers: Airspan Networks Holdings ( MIMO ) +104% . Baosheng Media Group ( BAOS ) +73% . Carvana CVNA +41% . Ideanomics ( IDEX ) +23% . ThermoGenesis Holdings ( THMO ) +23% . Rigetti Computing ( RGTI ) ...
2023-06-07 17:31:50 ET Gainers: 4D Molecular Therapeutics( FDMT ) +21% . Semtech Corporation ( SMTC ) +15% . Acorda Therapeutics ( ACOR ) +10% . scPharmaceuticals ( SCPH ) +7% . Kezar Life Sciences ( KZR ) +6% . Loser...
2023-06-05 17:18:34 ET Gainers: GitLab ( GTLB ) +19% . HealthEquity ( HQY ) +6% . Kezar Life Sciences ( KZR ) +5% . Ultragenyx Pharmaceutical ( RARE ) +4% . Vaxxinity ( VAXX ) +3% . Losers: Chijet Motor Compan...
Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-Founder and Chief Executive Officer, and Noreen R. Henig, M.D., Chief Medica...
2023-05-11 17:40:01 ET Kezar Life Sciences press release ( NASDAQ: KZR ): Q1 GAAP EPS of -$0.31. Cash, cash equivalents and marketable securities totaled $257.7 million as of March 31, 2023 For further details see: Kezar Life Sciences GAAP EPS of -$0.31
PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis on track to initiate in first half of 2023 KZR-261 dose escalation study continues to progress; the dose expansion study expected to initiate in second half of 2023 Cash, cash equivalents and marketable se...
(NewsDirect) Kalamazoo Resources Ltd (ASX:KZR) CEO Luke Reinehr tells Proactive the company is set to spin out its Australian lithium projects into a new ASX-listed exploration company, via a demerger and concurrent initial public offering (IPO) of Kali Metals Ltd (proposed ASX code: KM1). He...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...